| scholarly article | Q13442814 |
| P2093 | author name string | T Jake Liang | |
| P2860 | cites work | The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity | Q24307583 |
| Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 | ||
| Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees | Q24685256 | ||
| Regulation of hepatic innate immunity by hepatitis C virus | Q26824743 | ||
| Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection | Q27469507 | ||
| Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase | Q27469720 | ||
| Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders | Q27472760 | ||
| Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles | Q27472884 | ||
| Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C | Q27478257 | ||
| Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up | Q27480414 | ||
| Adaptive Immunity to the Hepatitis C Virus | Q37805839 | ||
| Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses | Q37825527 | ||
| Trends in vaccine adjuvants. | Q37867107 | ||
| Viral vectors as vaccine platforms: deployment in sight | Q37868123 | ||
| Developments in virus-like particle-based vaccines for infectious diseases and cancer | Q37951525 | ||
| T-cell-inducing vaccines - what's the future | Q37951575 | ||
| Hepatitis C virus evasion mechanisms from neutralizing antibodies | Q37967737 | ||
| Alum adjuvant: some of the tricks of the oldest adjuvant | Q37969028 | ||
| Animal models for the study of hepatitis C virus infection and related liver disease | Q38005793 | ||
| Anti-hepatitis C virus drugs in development | Q38005796 | ||
| Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes | Q39684938 | ||
| Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. | Q39866377 | ||
| Public health impact of antiviral therapy for hepatitis C in the United States | Q39939298 | ||
| Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo | Q40178086 | ||
| Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. | Q40209502 | ||
| Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes | Q41733978 | ||
| Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains | Q42951318 | ||
| Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. | Q42978347 | ||
| Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function | Q42979305 | ||
| Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. | Q42980990 | ||
| Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. | Q42984512 | ||
| Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort | Q42984783 | ||
| Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway | Q42990432 | ||
| A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees | Q42998134 | ||
| Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. | Q42999964 | ||
| Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine | Q43029925 | ||
| Failure to infect rhesus monkeys with hepatitis C virus strains of genotypes 1a, 2a or 3a. | Q43031832 | ||
| Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity | Q43036305 | ||
| A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. | Q43038008 | ||
| Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution | Q43038348 | ||
| Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies | Q43041465 | ||
| T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections | Q43048650 | ||
| Lessons from chimpanzee-based research on human disease: the implications of genetic differences. | Q45258100 | ||
| Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee | Q45422073 | ||
| Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers | Q46107112 | ||
| Unresponsiveness to a foreign antigen can be caused by self-tolerance | Q46860879 | ||
| A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers | Q49134267 | ||
| Nucleic acid testing to detect HBV infection in blood donors. | Q50548264 | ||
| Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada | Q57695969 | ||
| T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections | Q58802894 | ||
| The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein | Q27481009 | ||
| Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection | Q27485119 | ||
| Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein | Q27485143 | ||
| Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man | Q27485215 | ||
| Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses | Q27485952 | ||
| Mouse models for the study of HCV infection and virus–host interactions | Q27486807 | ||
| Evidence for Protection against Chronic Hepatitis C Virus Infection in Chimpanzees by Immunization with Replicating Recombinant Vaccinia Virus | Q27487131 | ||
| Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence | Q27488844 | ||
| Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire | Q27489598 | ||
| Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1 | Q27679280 | ||
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| Production of infectious hepatitis C virus in tissue culture from a cloned viral genome | Q27860899 | ||
| Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes | Q27861119 | ||
| Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group | Q28241816 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Vaccination of chimpanzees against infection by the hepatitis C virus | Q29615899 | ||
| Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections | Q29615900 | ||
| Rates of evolutionary change in viruses: patterns and determinants | Q29616174 | ||
| Analysis of a successful immune response against hepatitis C virus | Q29619507 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Adaptive immune responses in acute and chronic hepatitis C virus infection | Q29619722 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Unravelling hepatitis C virus replication from genome to function | Q29620056 | ||
| HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help | Q29620766 | ||
| Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response | Q29620891 | ||
| Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7 | Q33569555 | ||
| Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines | Q33683185 | ||
| Pathogenesis, natural history, treatment, and prevention of hepatitis C. | Q33841882 | ||
| Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection | Q33929089 | ||
| Rational antibody-based HIV-1 vaccine design: current approaches and future directions | Q33937285 | ||
| Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus | Q33955998 | ||
| The natural history of hepatitis C virus infection: host, viral, and environmental factors | Q33974693 | ||
| Hepatitis C vaccine: supply and demand | Q34011890 | ||
| Current and future therapies for hepatitis C virus infection | Q34036762 | ||
| Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. | Q34072573 | ||
| HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons | Q34247460 | ||
| Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. | Q34344995 | ||
| Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine | Q34373275 | ||
| Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors | Q34515995 | ||
| Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response | Q34552781 | ||
| Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource | Q34586710 | ||
| Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficiency virus type 1 infection in chimpanzees | Q34717558 | ||
| A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. | Q34733367 | ||
| Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins | Q34788785 | ||
| Antibodies, viruses and vaccines | Q34810301 | ||
| A genetically humanized mouse model for hepatitis C virus infection | Q35174543 | ||
| Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees | Q35249069 | ||
| Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope | Q35404598 | ||
| Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus | Q35465926 | ||
| Cross-genotype immunity to hepatitis C virus | Q35543288 | ||
| Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively | Q35557115 | ||
| Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion | Q35741969 | ||
| Host genetic determinants in hepatitis C virus infection | Q35753723 | ||
| Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States | Q35866205 | ||
| Neutralizing antibody response during acute and chronic hepatitis C virus infection | Q35971609 | ||
| Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection | Q36018953 | ||
| Acute hepatitis C: a multifaceted disease | Q36054683 | ||
| Evolution of infection control in Egypt: achievements and challenges | Q36470401 | ||
| Peginterferon and ribavirin for chronic hepatitis C. | Q36675912 | ||
| Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses | Q36829643 | ||
| Antiviral agents and HIV prevention: controversies, conflicts, and consensus | Q36836680 | ||
| Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity | Q37163082 | ||
| Adaptive immune features of natural killer cells | Q37172503 | ||
| Post-step modifications for research on HIV vaccines | Q37287027 | ||
| The coming of age of virus-like particle vaccines | Q37309265 | ||
| Immunology of TLR-independent vaccine adjuvants | Q37506781 | ||
| Adjuvant activity of cytokines | Q37680764 | ||
| Application of electroporation in DNA vaccination protocols | Q37760958 | ||
| Immunomodulators as adjuvants for vaccines and antimicrobial therapy | Q37800180 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 869-878 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Current progress in development of hepatitis C virus vaccines | |
| P478 | volume | 19 |
| Q40536482 | "Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research? |
| Q35861251 | A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice |
| Q35837765 | A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine |
| Q35606341 | Activation and evasion of antiviral innate immunity by hepatitis C virus. |
| Q59351582 | Approaches, Progress, and Challenges to Hepatitis C Vaccine Development |
| Q35942829 | Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding |
| Q26992256 | Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases |
| Q27469019 | Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus |
| Q35998417 | Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? |
| Q41620798 | Cell Spheroids with Enhanced Aggressiveness to Mimic Human Liver Cancer In Vitro and In Vivo |
| Q34078846 | Chronic HCV infection affects the NK cell phenotype in the blood more than in the liver. |
| Q52729536 | DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity. |
| Q56395915 | Defining Breadth of Hepatitis C Virus Neutralization |
| Q47548062 | Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus |
| Q39333862 | Designing an HCV vaccine: a unique convergence of prevention and therapy? |
| Q40151324 | Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. |
| Q36579835 | Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. |
| Q35641517 | Dynamic Interaction of Stress Granules, DDX3X, and IKK-α Mediates Multiple Functions in Hepatitis C Virus Infection |
| Q91807800 | Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins |
| Q38683495 | Effects of microvirin monomers and oligomers on hepatitis C virus. |
| Q61318668 | Engineered exosomes boost the HCV NS3-specific CD8+ T lymphocyte immunity in humans |
| Q39871877 | Evaluation of antiviral drug synergy in an infectious HCV system |
| Q38778496 | Experimental models of hepatitis B and C - new insights and progress |
| Q41549572 | Experimental transmission of equine hepacivirus in horses as a model for hepatitis C virus |
| Q36290295 | Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1 |
| Q41205806 | Functional characterization of p7 viroporin from hepatitis C virus produced in a cell-free expression system. |
| Q36096436 | Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance |
| Q37077112 | Global control of hepatitis C: where challenge meets opportunity |
| Q27928014 | Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential |
| Q90425686 | HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen |
| Q26738856 | Hepatitis C Viral Infection in Children: Updated Review |
| Q39238761 | Hepatitis C treatment as prevention: evidence, feasibility, and challenges |
| Q35270150 | Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war? |
| Q57162382 | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
| Q34008754 | Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy |
| Q38265395 | Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies |
| Q59354643 | Hepatitis C virus manipulates humans as its favorite host for long term relationship |
| Q38856649 | Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies |
| Q35501190 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade |
| Q26799141 | Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? |
| Q40679311 | Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents |
| Q35762467 | High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors |
| Q34178628 | Immune control and failure in HCV infection--tipping the balance |
| Q40858743 | Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy. |
| Q38885002 | Immune responses and immunopathology in acute and chronic viral hepatitis |
| Q26866955 | Immune responses to HCV and other hepatitis viruses |
| Q40248234 | Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates |
| Q50043345 | Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. |
| Q41035955 | Innate and Adaptive Immune Responses in Chronic HCV Infection |
| Q38844555 | Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. |
| Q38492768 | Large animal models for vaccine development and testing. |
| Q39403799 | Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection |
| Q37354049 | Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development |
| Q38248452 | Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection |
| Q35242585 | Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance |
| Q60960505 | Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice |
| Q92592914 | Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance |
| Q47104574 | Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. |
| Q36736683 | Prolactin Regulatory Element Binding Protein Is Involved in Hepatitis C Virus Replication by Interaction with NS4B. |
| Q33759224 | Protective immunity against hepatitis C: many shades of gray. |
| Q34594986 | Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization |
| Q59356260 | Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies |
| Q34470890 | Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. |
| Q64089872 | Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships |
| Q36433960 | Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification |
| Q28079102 | State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization |
| Q28084946 | Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses |
| Q39785930 | Synthesis and Anti-HCV Activity of 4-Hydroxyamino α-Pyranone Carboxamide Analogues. |
| Q36270505 | Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein |
| Q40730329 | Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism |
| Q37718978 | T cell responses to viral infections - opportunities for Peptide vaccination |
| Q37683966 | Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver. |
| Q37717076 | The "hidden" epidemic: a snapshot of Moroccan intravenous drug users |
| Q47608448 | The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis |
| Q34481429 | The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. |
| Q56669525 | The role of the Primary Healthcare Network in Iran in hepatitis C virus elimination by 2030 |
| Q33365202 | The synthetic biology puzzle: a qualitative study on public reflections towards a governance framework |
| Q37699395 | Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. |
| Q38613576 | Unraveling hepatitis C virus structure |
| Q42987741 | What's next for hepatitis C virus research? |
Search more.